In our study, we have shown that using target mitochondrial and nuclear genes to identify the origin of ccf-DNA in blood serum in PD patients by ddPCR enabled us to quantify ccf-DNA, which could be used in the future for optimalisation PD therapy. This evidence concerns the gene PITX1 and Parkinson disease.